Atai Beckley N.V. - 19 Apr 2024 Form 4 Insider Report for IntelGenx Technologies Corp.

Role: 10%+ Owner
Signature: ATAI Life Sciences N.V., By: /s/ Florian Brand, Chief Executive Officer
Issuer symbol: N/A
Transactions as of: 19 Apr 2024
Net transactions value: +$1,000,000
Form type: 4
Filing time: 03 May 2024, 16:05:22 UTC
Previous filing: 12 Mar 2024
Next filing: 27 Sep 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IGXT	Convertible Notes	Other	$1,000,000				$10,500,000	19 Apr 2024	Common Stock	5,405,405	$0.1850	By ATAI Life Sciences AG	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On April 19, 2024, pursuant to the Third Amended and Restated Loan Agreement, ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Any accrued interest outstanding under the loan may be converted into shares of Common Stock at the five day volume weighted average price of the shares, less the maximum permitted discount under certain applicable rules, ending on the day that is the second business day before the day the interest becomes due and payable.
F2	Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein.

Content

On April 19, 2024, pursuant to the Third Amended and Restated Loan Agreement, ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Any accrued interest outstanding under the loan may be converted into shares of Common Stock at the five day volume weighted average price of the shares, less the maximum permitted discount under certain applicable rules, ending on the day that is the second business day before the day the interest becomes due and payable.

Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein.